Welcome to our dedicated page for GNCA news (Ticker: GNCA), a resource for investors and traders seeking the latest updates and insights on GNCA stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect GNCA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of GNCA's position in the market.
Genocea Biosciences (Nasdaq: GNCA) announced its senior leadership will present at various conferences in January 2022. Key events include the Longwood Healthcare Leaders Winter Webconference on January 6, addressing innovations in cell therapy, and the LifeSci Partners 11th Annual Corporate Access Event on January 7, discussing oncology cell therapy. Additionally, a corporate update will be delivered at the H.C. Wainwright BIOCONNECT Virtual Conference on January 10, followed by participation in Advanced Therapies Week on January 26. Genocea aims to provide life-changing immunotherapies for cancer patients.
Genocea Biosciences (Nasdaq: GNCA) has announced a collaboration with Janssen Biotech to explore neoantigen immunogenicity in cancer vaccines. This agreement includes R&D funding and a technology access fee for Genocea's ATLAS platform. Additionally, Genocea reported significant advancements in its Phase 1/2a TiTAN trial for GEN-011, a targeted T cell therapy. The trial has yielded promising results, with preliminary data expected soon. The company continues to advance its immunotherapy candidates aimed at improving cancer treatment outcomes.
Genocea Biosciences (Nasdaq: GNCA), a biopharmaceutical company focused on immunotherapies, will have CEO Chip Clark participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on November 17 at 1:20 PM ET. Investors can access the live webcast through the investor relations section of the Genocea website and will be available for 90 days post-event. The company is advancing its GEN-011 and GEN-009 clinical trials, utilizing its ATLAS™ platform to develop innovative cancer treatments.
Genocea Biosciences, Inc. (Nasdaq: GNCA) reported a positive business update for Q3 2021, highlighting progress in its TiTAN™ clinical trial for GEN-011. Initial data is expected in early 2022. The company also appointed Jennifer Herron to its Board of Directors, enhancing its leadership in commercialization. Financially, as of September 30, 2021, cash and cash equivalents stood at $48.9 million, while net loss decreased to $3.6 million from $4.6 million YoY. R&D expenses rose to $9.5 million, driven by clinical costs for GEN-011. Genocea's cash runway extends into Q3 2022.
Genocea Biosciences (NASDAQ: GNCA) will host its third quarter 2021 corporate update on October 28th at 8:30 a.m. E.T. Participants can join the conference by calling (844) 826-0619 domestically or (315) 625-6883 internationally, using conference ID 8729366. The event will also be available via a live audio webcast on their investor relations page. A replay will be accessible approximately two hours post-event for 90 days. Genocea focuses on developing innovative cancer immunotherapies through its ATLAS™ platform, identifying tumor antigens to optimize targeted therapies.
Genocea Biosciences (Nasdaq: GNCA), a biopharmaceutical company focused on neoantigen immunotherapies, announced key presentations at several upcoming conferences in October 2021. Notable events include the AACR Tumor Immunology and Immunotherapy conference, where GEN-011 will be discussed, and the CMO Summit, addressing communication after clinical trial failures. The company aims to showcase its innovative research in cancer therapies, leveraging its ATLAS™ platform to identify effective tumor targets.
Genocea Biosciences, Inc. (GNCA) has appointed Jennifer Herron, former Chief Commercial Officer at ADC Therapeutics, to its board of directors. This strategic move aims to enhance Genocea's commercial expertise as it advances its pipeline, including the neoantigen-targeted T cell therapy GEN-011 for solid tumors. Herron, with her vast experience in leading commercialization strategies at major biopharmaceutical companies, is expected to significantly contribute to Genocea's growth and success. The company's ATLAS platform also shows potential for optimizing cancer immunotherapy.
Genocea Biosciences (Nasdaq: GNCA) plans to present at multiple virtual conferences in September 2021, highlighting its development of neoantigen immunotherapies. Notable events include the Next Generation Cancer Vaccine Development Summit on September 9 at 1:00 p.m. ET, focusing on identifying specific tumor targets. Additionally, Genocea will participate in the H.C. Wainwright 22nd Annual Global Investment Conference on September 13 at 7:00 a.m. ET and the Baird Global Healthcare Conference on September 15 at 11:25 a.m. ET.
Genocea Biosciences (Nasdaq: GNCA) provided a Q2 2021 update, highlighting progress in its GEN-011 and GEN-009 clinical programs. The GEN-011 neoantigen-targeted therapy is currently in a Phase 1/2a trial, with initial patient dosing complete. Preliminary results are expected by early 2022. For GEN-009, long-term data showed tumor reductions in CPI-sensitive patients, with a median progression-free duration of 15 months. Financially, as of June 30, 2021, Genocea reported $60.4 million in cash, a net loss of $4.3 million, and extended its cash runway to late 2022.
Genocea Biosciences (NASDAQ: GNCA) will host its Q2 2021 financial results and corporate update on July 29, 2021, at 8:30 a.m. E.T. Participants can join via phone at (844) 826-0619 (domestic) or (315) 625-6883 (international), using conference ID 6789021. A live audio webcast will be accessible on the Genocea investor relations website. The event's replay will be available for 90 days post-event. Genocea focuses on cancer immunotherapies utilizing its ATLAS™ platform, with ongoing clinical trials for GEN-011 and GEN-009.
